Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
ALLR Stock News and Mentions of Allarity Therapeutics, Inc. Stocktwits
Updated: April 26, 2024 (09:55)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Allarity Therapeutics Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Allarity Therapeutics, Inc. (ALLR).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Allarity Therapeutics stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Allarity Therapeutics, Inc. (ALLR)
April 17, 2024 (13:10) / "GlobeNewswire" (by Allarity Therapeutics)
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550 ( b ) ( 1 )
Boston ( April 17, 2024 ) -Allarity Therapeutics, Inc. ( "Allarity" or the "Company" ) ( NASDAQ: ALLR ) , a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it had been granted an extension until May 14, 2024, to regain compliance ...
In Article Trend: Neutral
April 15, 2024 (10:04) / "Business Insider" (by Avi Kapoor)
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Why Medical Properties Trust Shares Are Trading Higher By Around 13%. Here Are 20 Stocks Moving Premarket - Markets Insider ...
In Article Trend: Neutral
April 15, 2024 (09:45) / "Benzinga" (by Avi Kapoor)
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Medical Properties Trust ( NYSE:MPW )
Shares of Medical Properties Trust, Inc. MPW rose sharply in today's pre-market trading after the company announced that it sold its majority interest in Utah Hospitals. Medical Properties Trust shares jumped 13.1% to $4.51 in pre-market trading. Here are some other stocks moving in pre-market ...
In Article Trend: Neutral
April 12, 2024 (09:32) / "Benzinga" (by Avi Kapoor)
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket - NextPlat ( NASDAQ:NXPL )
Shares of NextPlat Corp NXPL rose sharply in today's pre-market trading after the company reported consolidated 2023 revenues of $37.8 million, up 222% year over year NextPlat shares surged 29.8% to $1.96 in pre-market trading. Here are some other stocks moving in pre-market trading.
In Article Trend: Neutral
April 11, 2024 (10:14) / "Benzinga" (by Avi Kapoor)
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket - Rallybio ( NASDAQ:RLYB )
Shares of Rallybio Corporation RLYB rose sharply in today's pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Rallybio shares jumped rose 77.9% to $2.90 in pre-market trading.
In Article Trend: Neutral
April 8, 2024 (10:05) / "Business Insider" (by Avi Kapoor)
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%. Here Are 20 Stocks Moving Premarket - Markets Insider ...
In Article Trend: Neutral
April 8, 2024 (09:15) / "Benzinga" (by Avi Kapoor)
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Antelope Ent Hldgs ( NASDAQ:AEHL ) , Allarity Therapeutics ( NASDAQ:ALLR )
Shares of Esperion Therapeutics, Inc. ESPR shares rose sharply during today's pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEXLETOL® tablets in diverse populations. Esperion Therapeutics shares climbed 7.1% to $3.47 pre-market trading.
In Article Trend: Neutral
April 5, 2024 (09:45) / "Benzinga" (by Avi Kapoor)
Why Reliance Global Group Shares Are Trading Lower By Around 11%; Here Are 20 Stocks Moving Premarket - Reliance Global Group ( NASDAQ:RELI )
Shares of Reliance Global Group, Inc. RELI fell sharply in today's pre-market trading after reporting financial results for the year ended Dec 31, 2023. Reliance Global Group posted a net loss of $12.0 million for 2023, compared to net income of $6.5 million in 2022..
In Article Trend: Neutral
April 4, 2024 (13:15) / "GlobeNewswire" (by Inc.)
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
Boston ( April 4, 2024 ) - Allarity Therapeutics, Inc. ( "Allarity" or the "Company" ) ( NASDAQ: ALLR ) , a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the implementation of a reverse stock split of its outstanding shares of ...
In Article Trend: Neutral
March 27, 2024 (12:30) / "Benzinga" (by Globe Newswire)
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer - Allarity Therapeutics ( NASDAQ:ALLR )
The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of IXEMPRA® and dovitinib is de-prioritized The Company has been able to reduce costs materially
In Article Trend: Neutral
March 27, 2024 (12:30) / "GlobeNewswire" (by Allarity Therapeutics)
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
• The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development • Further development of IXEMPRA® and dovitinib is de-prioritized • The Company has been able to reduce costs materially
In Article Trend: Neutral
March 25, 2024 (11:30) / "GlobeNewswire" (by Allarity Therapeutics)
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550 ( a ) ( 2 ) and 5550 ( b ) ( 1 )
Boston ( March 25, 2024 ) - Allarity Therapeutics, Inc. ( "Allarity" or the "Company" ) ( NASDAQ: ALLR ) , a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that the Company has been granted a formal extension until April 24, 2024 to ...
In Article Trend: Neutral
March 8, 2024 (12:15) / "GlobeNewswire" (by Allarity Therapeutics)
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
Boston ( March 8, 2024 ) - Allarity Therapeutics, Inc. ( "Company" ) ( NASDAQ: ALLR ) , a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results for the year ended December 31, 2023, and provided a general business update.
In Article Trend: Neutral
February 28, 2024 (11:00) / "GlobeNewswire" (by Allarity Therapeutics)
Allarity Therapeutics to Present at Biomarkers 2024
Boston ( February 28, 2024 ) - Allarity Therapeutics, Inc. ( "Allarity" or the "Company" ) ( NASDAQ: ALLR ) , a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at Biomarkers 2024.
In Article Trend: Neutral
Related stocks from Healthcare sector
Sundial Growers Inc. (SNDL)
Galera Therapeutics, Inc. (GRTX)
Gilead Sciences, Inc. (GILD)
PepGen Inc. (PEPG)
Turning Point Therapeutics, Inc. (TPTX)
Aerie Pharmaceuticals, Inc. (AERI)
HOOKIPA Pharma Inc. (HOOK)
Pacific Biosciences of California, Inc. (PACB)
Absci Corporation (ABSI)
ImmunityBio, Inc. (IBRX)
This website uses cookies to ensure you get the best experience on our website